Avidity Financial Statements From 2010 to 2026

RNA Stock

USD 72.61 0.07 0.1%

Avidity Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Avidity Biosciences' valuation are provided below:

Gross Profit

-467.3 M

Market Capitalization

10.9 B

Enterprise Value Revenue

435.4789

Revenue

20.9 M

Earnings Share

(4.19)

We have found one hundred twenty available fundamental signals for Avidity Biosciences, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Avidity Biosciences prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road.

Avidity Biosciences Total Revenue

9.15 Million

Check Avidity Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Avidity Biosciences' main balance sheet or income statement drivers, such as Interest Expense of 6.9 M, Total Revenue of 9.2 M or Research Development of 366.6 M, as well as many indicators such as Price To Sales Ratio of 424, Dividend Yield of 1.0E-4 or PTB Ratio of 2.15. Avidity financial statements analysis is a perfect complement when working with Avidity Biosciences Valuation or Volatility modules.

Build AI portfolio with Avidity Stock

Check out the analysis of Avidity Biosciences Correlation against competitors.

For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.

Avidity Biosciences Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

1.9 B

1.8 B

450 M

Slightly volatile

Other Current Liabilities

78.2 M

74.4 M

22.4 M

Slightly volatile

Total Current Liabilities

118.4 M

112.7 M

35.2 M

Slightly volatile

Other Liabilities

1.1 M

5.6 M

Slightly volatile

Accounts Payable

5 M

9.7 M

4.1 M

Slightly volatile

Cash

185.1 M

252.8 M

126.9 M

Slightly volatile

Other Assets

0.86

0.9

323 K

Slightly volatile

Long Term Debt

1.5 M

1.6 M

4.5 M

Slightly volatile

Other Current Assets

15.2 M

14.5 M

4.2 M

Slightly volatile

Total Liabilities

167.8 M

159.8 M

73.8 M

Slightly volatile

Intangible Assets

896.8 K

939.6 K

1.1 M

Slightly volatile

Common Stock

10.3 K

10.8 K

210.1 K

Slightly volatile

Property Plant Equipment

18.1 M

17.3 M

6.8 M

Slightly volatile

Short and Long Term Debt Total

8.7 M

7.8 M

9.1 M

Slightly volatile

Property Plant And Equipment Net

10.7 M

21 M

6.2 M

Slightly volatile

Non Current Assets Total

26.1 M

24.8 M

7.8 M

Slightly volatile

Non Currrent Assets Other

4 M

3.8 M

874.8 K

Slightly volatile

Cash And Short Term Investments

1.8 B

1.7 B

417.8 M

Slightly volatile

Common Stock Total Equity

3.4 K

3.6 K

227.4 K

Slightly volatile

Common Stock Shares Outstanding

134.7 M

128.3 M

46.3 M

Slightly volatile

Long Term Debt Total

1.5 M

1.6 M

4.8 M

Slightly volatile

Liabilities And Stockholders Equity

1.9 B

1.8 B

436 M

Slightly volatile

Non Current Liabilities Total

36.5 M

36.8 M

42.1 M

Very volatile

Property Plant And Equipment Gross

31.7 M

30.2 M

8.8 M

Slightly volatile

Short and Long Term Debt

3 M

3.2 M

2.8 M

Slightly volatile

Total Current Assets

1.9 B

1.8 B

428.2 M

Slightly volatile

Non Current Liabilities Other

38.5 K

40.5 K

139.1 K

Slightly volatile

Short Term Debt

4 M

4.4 M

3.3 M

Slightly volatile

Current Deferred Revenue

12.2 M

24.1 M

8.1 M

Slightly volatile

Net Receivables

34.1 M

32.5 M

6.9 M

Slightly volatile

Short Term Investments

1.5 B

302.5 M

Slightly volatile

Avidity Biosciences Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Revenue

9.2 M

12.5 M

6.9 M

Pretty Stable

Research Development

366.6 M

349.1 M

96.5 M

Slightly volatile

Cost Of Revenue

2.4 M

2.5 M

12.5 M

Slightly volatile

Depreciation And Amortization

3.4 M

3.2 M

1 M

Slightly volatile

Selling General Administrative

104.1 M

99.2 M

26.4 M

Slightly volatile

Other Operating Expenses

470.7 M

448.3 M

119.9 M

Slightly volatile

Total Operating Expenses

470.7 M

448.3 M

119.8 M

Slightly volatile

Reconciled Depreciation

3.4 M

3.2 M

1 M

Slightly volatile

Selling And Marketing Expenses

1.7 M

1.9 M

2.1 M

Slightly volatile

Avidity Biosciences Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Capital Expenditures

8.5 M

8.1 M

2.5 M

Slightly volatile

Change To Account Receivables

557.6 K

627.3 K

684.7 K

Slightly volatile

Total Cash From Financing Activities

1.4 B

301.8 M

Slightly volatile

End Period Cash Flow

205.8 M

256.1 M

117.3 M

Slightly volatile

Sale Purchase Of Stock

485.1 K

510.6 K

4.6 M

Very volatile

Stock Based Compensation

62 M

59.1 M

15.3 M

Slightly volatile

Begin Period Cash Flow

200.2 M

213.2 M

102.8 M

Slightly volatile

Depreciation

3.4 M

3.2 M

1 M

Slightly volatile

Change To Netincome

32 M

30.5 M

10.3 M

Slightly volatile

Change To Liabilities

8.2 M

15.2 M

5.4 M

Slightly volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Price To Sales Ratio

424

342

936

Slightly volatile

Dividend Yield

1.0E-4

Slightly volatile

Days Sales Outstanding

893

851

210

Slightly volatile

Stock Based Compensation To Revenue

4.45

4.24

1.4357

Slightly volatile

Capex To Depreciation

1.85

2.29

1.2553

Slightly volatile

EV To Sales

396

320

931

Slightly volatile

Payables Turnover

0.36

0.38

3.6177

Slightly volatile

Sales General And Administrative To Revenue

7.48

7.12

5.7197

Pretty Stable

Research And Ddevelopement To Revenue

26.33

25.07

19.9134

Very volatile

Capex To Revenue

0.61

0.58

0.2596

Slightly volatile

Cash Per Share

6.96

12.11

4.776

Slightly volatile

Days Payables Outstanding

648

1 K

462

Slightly volatile

Current Ratio

9.37

14.16

6.536

Slightly volatile

Receivables Turnover

0.42

0.44

5.0809

Slightly volatile

Capex Per Share

0.0371

0.057

0.0257

Slightly volatile

Revenue Per Share

0.12

0.0879

0.0811

Slightly volatile

Interest Debt Per Share

0.0666

0.0701

0.3534

Slightly volatile

Debt To Assets

0.0048

0.005

1.3801

Slightly volatile

Days Of Payables Outstanding

648

1 K

462

Slightly volatile

Ebt Per Ebit

1.13

0.98

1.0516

Slightly volatile

Quick Ratio

9.38

14.16

6.5432

Slightly volatile

Net Income Per E B T

0.85

0.96

1.0453

Slightly volatile

Cash Ratio

2.45

2.58

3.7783

Slightly volatile

Days Of Sales Outstanding

893

851

210

Slightly volatile

Free Cash Flow Operating Cash Flow Ratio

0.81

0.92

0.99

Slightly volatile

Fixed Asset Turnover

0.65

0.69

0.9929

Pretty Stable

Debt Ratio

0.0048

0.005

1.3801

Slightly volatile

Price Sales Ratio

424

342

936

Slightly volatile

Asset Turnover

0.0076

0.008

0.0573

Slightly volatile

Avidity Biosciences Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

471.5 M

530.5 M

579 M

Slightly volatile

Enterprise Value

477.3 M

537 M

586.1 M

Slightly volatile

Avidity Fundamental Market Drivers

Avidity Upcoming Events

	27th of February 2024 Upcoming Quarterly Report	View
	14th of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	27th of February 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

About Avidity Biosciences Financial Statements

Avidity Biosciences stakeholders use historical fundamental indicators, such as Avidity Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Avidity Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Avidity Biosciences' assets and liabilities are reflected in the revenues and expenses on Avidity Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Avidity Biosciences. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Current Deferred Revenue	24.1 M	12.2 M
Total Revenue	12.5 M	9.2 M
Cost Of Revenue	2.5 M	2.4 M
Stock Based Compensation To Revenue	4.24	4.45
Sales General And Administrative To Revenue	7.12	7.48
Research And Ddevelopement To Revenue	25.07	26.33
Capex To Revenue	0.58	0.61
Revenue Per Share	0.09	0.12
Ebit Per Revenue	(39.99)	(41.99)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

GOOG	Alphabet Inc Class C
V	Visa Class A
MSFT	Microsoft

When determining whether Avidity Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Avidity Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Avidity Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Avidity Biosciences Stock:

How To Invest In Avidity

Details

Is Avidity Stock a good investment?

Details

What is Avidity Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Avidity Biosciences Correlation against competitors.

For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.

You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avidity Biosciences. If investors know Avidity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avidity Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.19)

Revenue Per Share

0.159

Quarterly Revenue Growth

4.34

Return On Assets

(0.20)

Return On Equity

(0.32)

The market value of Avidity Biosciences is measured differently than its book value, which is the value of Avidity that is recorded on the company's balance sheet. Investors also form their own opinion of Avidity Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Avidity Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avidity Biosciences' market value can be influenced by many factors that don't directly affect Avidity Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Avidity Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avidity Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avidity Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Avidity Financial Statements From 2010 to 2026

Avidity Biosciences Total Revenue

9.15 Million

Avidity Biosciences Balance Sheet

Avidity Biosciences Income Statement

Avidity Biosciences Cash Flow Statement

Financial Ratios

Avidity Biosciences Valuation Data

Avidity Fundamental Market Drivers

Avidity Upcoming Events

About Avidity Biosciences Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY